TMEM209

Across TCGA pan-cancer cohorts, TMEM209 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM209 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TMEM209 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM209 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

OV, SKCM, and UCEC are the cancer types where TMEM209 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	III,IV	1.000	0.366	.023	18	view →
SKCM	DFS	Median	All	0.015	0.758	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM209–OV (DFS)

Open the OV breakdown →